Scientific Programme


arrow-circle-sml Medical Oncology
arrow-circle-sml Surgical Oncology
arrow-circle-sml Skin Imaging
arrow-circle-sml Dermoscopy
arrow-circle-sml Clinical Diagnosis
arrow-circle-sml Public Health
arrow-circle-sml Epidemiology
arrow-circle-sml Pathology
arrow-circle-sml Immunotherapy
arrow-circle-sml Targeted Therapy
arrow-circle-sml Genomic Research
arrow-circle-sml International Guidelines Development
arrow-circle-sml Merkel Cell Carcinoma
arrow-circle-sml Basal Cell Carcinoma
arrow-circle-sml Squamous Cell Carcinoma


arrow-circle-sml Epigenetics and Metabolism
arrow-circle-sml Genetics and Genomics
arrow-circle-sml Immunotherapy: New Targets and Mechanisms of Resistance
arrow-circle-sml Late Breaking Basic Science and Clinical Updates
arrow-circle-sml Melanoma and Melanocyte Biology
arrow-circle-sml Targeted Therapies: New Targets and Mechanisms of Resistance
arrow-circle-sml Tumour Heterogeneity, Plasticity and Drug Resistance
arrow-circle-sml Tumour Microenvironment and Drug Resistance

Plenary 1 – Melanoma epidemiology and early diagnosis
“Neville Davis and Gerald Milton Lecture”
Keynote Address:
Adèle Green, Australia – The changing epidemiology of
cutaneous melanoma: 1967-2017
Harald Kittler, Austria – Delays have dangerous ends! Who benefits from early detection?
Iris Zalaudek, Austria – No one should die from melanoma; Vision or Impossible Mission?
Allan Halpern, USA – The changing landscape of melanoma detection

Plenary 2 – Society for Melanoma Research
Keynote Address: Levi Garraway, USA
Additional speakers to be confirmed

Plenary 3 – Staging, surgery and targeted therapies for melanoma
Keynote Address: Axel Hauschild, Germany – Targeted therapies and combination approaches in metastatic melanoma
Jeffrey Gershenwald, USA – The new AJCC melanoma classification
Alexander van Akkooi, Netherlands – Controversies on lymph node management
John Thompson, Australia – Surgery for stage 4 melanoma patients: Is it still worthwhile?

Plenary 4 Immuno-oncology in melanoma
Keynote Address: Antoni Ribas, USA – Rationale for immunotherapy in melanoma
Caroline Robert, France – Latest results of immunotherapy in melanoma
Jacob Schachter, Israel – Adaptive T-cell transfer in the era of checkpoint inhibition
Reinhard Dummer, Switzerland – Checkpoint inhibition beyond PD-1 and CTLA-4 inhibition

Plenary 5 – Future Perspectives and Congress Highlights
Keynote Address: Boris Bastian, USA – Unsolved questions in melanoma genesis
Grant McArthur, Australia – Genetic testing for skin cancer in 2017 and beyond
H Peter Soyer, Australia – Future perspectives of early detection of skin cancers
Georgina Long, Australia  – Highlights in melanoma from 2017

A sneak preview of the programme at a glance is now available for download.

Programme Changes

The organizer reserves the right to make changes if necessary. No full or partial refunds are made to the attendees in the event of cancellations or other changes in the programme. Please note that changes will be posted at the registration desk and at the entrance of the session halls. Participants will be informed about the changes.